eloralintide

News

Zealand hit as Roche-partnered obesity drug disappoints

Shares in Zealand lost a third of their value today, after the biotech reported phase 2 data with Roche-partnered weight-loss therapy petrelintide.

News

Lilly reports 20% weight loss with amylin-targeting drug

Eli Lilly has raised the stakes in the obesity market with positive midstage data for its amylin-targeting drug eloralintide.

News

Apogee buy delivers eczema trial win for AbbVie

AbbVie's long-acting IL-13 inhibitor zumilokibart, part of its $10.9bn Apogee buy, has shown efficacy in atopic dermatitis and will move into phase 3.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks